Integrated Diagnostics (OTCMKTS:IDGXF – Get Free Report) and Ginkgo Bioworks (NYSE:DNA – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.
Earnings & Valuation
This table compares Integrated Diagnostics and Ginkgo Bioworks”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Integrated Diagnostics | N/A | N/A | N/A | N/A | N/A |
| Ginkgo Bioworks | $170.15 million | 2.80 | -$312.76 million | ($5.01) | -1.46 |
Analyst Recommendations
This is a summary of current ratings and price targets for Integrated Diagnostics and Ginkgo Bioworks, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Integrated Diagnostics | 0 | 0 | 0 | 0 | 0.00 |
| Ginkgo Bioworks | 2 | 1 | 0 | 0 | 1.33 |
Ginkgo Bioworks has a consensus price target of $7.00, indicating a potential downside of 3.98%. Given Ginkgo Bioworks’ stronger consensus rating and higher possible upside, analysts clearly believe Ginkgo Bioworks is more favorable than Integrated Diagnostics.
Insider and Institutional Ownership
78.6% of Ginkgo Bioworks shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Integrated Diagnostics and Ginkgo Bioworks’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Integrated Diagnostics | N/A | N/A | N/A |
| Ginkgo Bioworks | -259.96% | -60.27% | -26.88% |
Summary
Ginkgo Bioworks beats Integrated Diagnostics on 5 of the 8 factors compared between the two stocks.
About Integrated Diagnostics
Integrated Diagnostics Holdings plc, a consumer healthcare company, provides various medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, including positron emission tomography computed tomography (PET-CT), magnetic resonance imaging (MRI), computed tomography (CT), mammography, ultrasound, x-ray, electromyography (EMG), electroencephalography, electroencephalogram (EEG), and electrocardiogram (ECG), as well as operates cath lab facilities. It operates in Egypt, Sudan, Jordan, Nigeria, and the Kingdom of Saudi Arabia. The company was founded in 1979 and is headquartered in Saint Helier, Jersey.
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Integrated Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integrated Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
